

Design and Estimation of Fast Dissolving Tablet by using Novel Techniques for Effective Treatment of Diabetes

Dillip Kumar Brahma, Neeraj sharma

Abstract: *Diabetes mellitus is a metabolic issue it is brought about by a flat out or relative absence of insulin that, among different outcomes, increments in plasma glucose fixation related to change hyperglycemia and unsettling influence of lipid digestion, starch digestion, additionally protein digestion. Glipizide, a second-gen sulfonylurea, is utilized with diet to bring down blood glucose in patients with diabetes mellitus type II. The essential method of activity of glipizide in exploratory creatures seems, by all accounts, to be the incitement of insulin emission from the beta cells of pancreatic islet tissue and is in this way reliant on working β -cells in the pancreatic islets. In human's glipizide seems to bring down the blood glucose intensely by invigorating the arrival of insulin from the pancreas, an impact subordinate after working β -cells in the pancreatic islets. In man, incitement of insulin discharge by glipizide because of a feast is undoubtedly vital. Fasting insulin levels are not raised even on long haul glipizide organization, yet the postprandial insulin reaction keeps on being upgraded after at any rate a half year of treatment.*

Keywords: *Diabetes mellitus, Glipizide, IDDM*

I. INTRODUCTION

The expression "Diabetes mellitus" is gotten from the Greek words dia (=through), keep up (=to go) and diabetes actually implies go through. The infection causes loss of weight as though the weight is gone through the urine. Despite the fact that it was known for quite a long time that the urine of patients with diabetes was sweet, it was not until 1674 that a doctor named Willis instituted the term "Diabetes Mellitus" (DM from the Greek word for honey [1]). Diabetes mellitus with retinopathy, neuropathy or nephropathy inconveniences covers an important hazard factor in atherosclerosis. It is outstanding that it is related with expanded generation of receptive oxygen species and a decrease in antioxidant safeguards. The diabetic prompted oxidative pressure is pathogenically significant in diabetic confusions [2]. It is an enduring disease whose worldwide spread has given it pandemic qualities. The prevalence for all age overall was DM is presently turning into a typical metabolic issue, coming about because of the powerlessness of our body's reaction to high level of blood glucose. "Type-II diabetes mellitus" is accounted for to be 90-95% off every single diabetic case [3].

Revised Manuscript Received on June 06, 2013.

Dillip Kumar Brahma, Research Scholar, Dept. of Pharmacy, Sri Satya Sai University of Technology & Medical Sciences, Sehore, Bhopal-Indore Road, Madhya Pradesh, India

Dr. Neeraj Sharma, Research Guide, Dept. of Pharmacy, Sri Satya Sai University of Technology & Medical Sciences, Sehore, Bhopal Indore Road, Madhya Pradesh, India

The epidemic idea of type II is intently connected with weight, and as per the WHO, in excess of 220 million individuals were experiencing it in 2009.

The quantity of individuals anticipated to experience the ill effects of type-II diabetes is anticipated to ascend more than 350 million by 2030 [4]. Striking development has been accomplished in the improvement of manufactured medications, however, examinations are being completed to find normal and financially savvy nourishment hotspots for overseeing hyperglycemia and hypertension-related with beginning times of type-II diabetes, through diets wealthy in vegetables, organic products, vegetables, herbs, and flavors. These plant nourishments comprise essential supplements, for example, "vitamins, minerals, dietary filaments", and increasingly significant bioactive mixes, for example, polyphenols and carotenoids that can have explicit structure-work benefits evaluated to be 2.8 percentage in 2000 and 4.4 percentage in 2030. Internationally, starting in 2010, an expected 285 million individuals had diabetes speaking to 6.6% of the world's grown-up populace, with an expectation that by 2030 the number of persons with diabetes will have ascended to 438 million. Today, there are 382 million individuals living with diabetes. A further 316 million with disabled glucose resilience are at high hazard from the illness a disturbing number that is set to arrive at 471 million by 2035. The expansion in frequency in creating nations pursues the pattern of urbanization and way of life changes, maybe above all a "Western-style" diet. This has recommended a natural (i.e., dietary) impact, yet that's small comprehension of the mechanism(s) at present, however, that's lot of theory, some of it most compellingly introduced. Diabetes is the 6th driving reason for death around the world. The most regular structure is type II diabetes which speaks to over 85% of the cases. Type-I represents 10% and explicit and gestational diabetes represents about 5%.

II. PATHOPHYSIOLOGY

Type-1 Diabetes (IDDM)

The insusceptible structure devastation of pancreatic beta-cells prompts an inadequacy of insulin expulsion which gets around the "metabolic" confusions related with IDDM. Notwithstanding the defeat of insulin emission, the capacity of "pancreatic alpha-cells" is likewise irregular and there is over the top discharge of glucagon in IDDM patients.

Regularly, hyperglycemia prompts diminished glucagon discharge; it may, in patients with IDDM, glucagon emission isn't stifled by hyperglycemia. An incorrect increase in the glucagon level aggravates metabolic disorders due to insufficient insulin.

The uncontrolled IDDM causes an expansion in liver glucose. At first, the glycogen stores in the liver are enacted, at that point "gluconeogenesis" in the liver is utilized to regulate glucose. The absence of insulin additionally averts the utilization of glucose in non-liver tissues. Specifically, in "fat tissue" and skeletal muscle, it invigorates insulin glucose take-up. This is achieved by transporting glucose-transported proteins transported by insulin into the plasma layer of these tissues. The decrease of the glucose uptake by the peripheral tissue, therefore, leads to a decrease of the glucose treatment rate. The combination of an increase in liver glucose production and a decrease in secondary tissue assimilation results in an increase in plasma glucose levels. If the kidney line is limited to glucose storage, glycosuria continues. Glucose is an osmotic diuretic and the degree of renal failure of glucose is related to the loss of water and electrolytes. The eventual outcome of the loss of water (and all things considered volume) prompts the sanctioning of the thirst segment (polydipsia). The negative caloric equality, which results from glycosuria and tissue catabolism prompts an extension in appetite and sustenance utilization that is polyphagia [6].

Effect on Lipid Metabolism

An important task of insulin is to build the essentialness of nourishment after eating as glycogen in hepatocytes and

skeletal muscles. In gathering, insulin stimulates hepatocytes to blend and store triglycerides in fat tissue. The uncontrolled IDDM forms a fast collection of triglycerides, prompting an expansion in unsaturated fat levels without plasma. The absence of support for insulin prompts hypertriglyceridemia.

Effects on Protein

Insulin coordinates the amalgamation of a few capacities, either unequivocally or uncooperatively, which impact overall processing. Insulin by and large influences protein processing, growing the pace of protein unification and contracting the pace of protein abuse. In this way insulin deficiency will prepared to expanded catabolism of protein. The extended pace of proteolysis prompts raised centralization of amino acids in plasma [7]. "Gluconeogenic amino acids fill in as predecessors for hepatic and renal gluconeogenesis, which further adds to the hyperglycemia found in IDDM."

III. MATERIAL AND METHODS

Drug and Chemicals

Glipizide were gotten from Ipca Laboratories Ltd, Ratlam and different areas, for example, lactose, sodium starch glycolate and powder and were acquired from Mumbai.

Preparation Method

Glipizide were blended in with "lactose", glycol ate and sodium starch and, the powder was included. The mix was blended appropriately and separated (Table 1). The mix was packed to get ready tablets.

Table No. 1: Composition of Glipizide Fast Dissolving Tablet Ingredients

Excipients	F1	F2	F3	F4	F5
Glipizide	5	5	5	5	5
Croscarmellose	2	5	2	5	0
Sodium starch glycolate	3	3	6	6	0
Lactose	60	60	60	60	60
MCC	30	30	30	30	30
Magnesium stearate	5	5	5	5	5
Talc	3	3	3	3	3

Evaluation of Formulated Tablets Micromeritics

• Angle of Repose

The point of rest was resolved utilizing the static channel strategy. The mixture would transfer over the funnel that could be elevated perpendicularly until a concentrated reached to cone (h)-height. The range of the (r)-load was estimated and the point of rest (θ) was determined utilizing the equation.

$$\theta = \tan^{-1} (h / r)$$

• Bulk Density

Bulk density was unwavering by driving the mixture into a graduated cylinder. The mass (V)-volume and (M)-powder was determined. The below mentioned formula was used to calculate the mass density,

$$\text{Bulk density} = \frac{\text{Mass of Granules}}{\text{Volume}}$$

- **Tapped Density**

The estimating chamber comprising a well-known mass of mix was selected for a fixed time. The base (Vt)-volume involved in the chamber and the (M)-weight of the mix has estimated. The tapped thickness was determined utilizing the accompanying equation

$$\text{Tapped density} = \frac{\text{Weight of Blend}}{\text{Volume occupied in cylinder}}$$

- **Compressibility Index**

The most straightforward path for estimation of the free progression of concentrate is reduced, a sign of the straightforwardness through a material can be incited to stream is given by compressibility list (I) which is determined as pursues,

$$I = \frac{V_o - V_t}{V_{bx}}$$

Here, Vt is tapped volume and Vo is mass volume. The incentive underneath 15% demonstrates a powder which as a rule offers ascend to great stream qualities, while above 25% show poor flowability.

- **Hausner's Ratio**

Hausner's proportion is a roundabout file of simplicity of powder stream. It is determined by the accompanying recipe,

$$\text{Hausner ratio} = \frac{\text{Tapped density}}{\text{Bulk density}}$$

- **Thickness**

Vernier calliper (Mitutoya, Model CD-6 CS, Japan) was used to calculate Thickness of tablet.

- **Hardness**

Monsanto hardness analyzer (Sheetal Scientific Industries, Mumbai, India) was used estimate the crushing quality of the tablets. Three tablets from every definition bunch were tried haphazardly and the normal perusing noted.

- **Friability**

20 capsules were gauged and put in a Roche friabilator (Electrolab, India).

$$\text{Percentage friability} = \frac{\text{Initial weight} - \text{Final weight}}{\text{Initial weight}} \times 100$$

Twenty reweighed tablets were turned at 30 rpm for 5 min. The tablets were then taken and reweighed and the level of weight reduction was determined. The rate estimated according to the accompanying equation,

- **Weight Variation**

[After compression, 20 tablets were erratically selected and the normal weight determined. None of the tablets deviated more than $\pm 7.5\%$ from the average weight.

- **Wetting Time**

A piece (8 cm) round tissue paper folded twice in a (inner diameter = 9 cm) Petri dish containing ten ml saliva-like baby bed layout, pH 6.8, was placed. Three tablets of each definition were randomly selected and the normal wetting time was observed. The results are summarized in Table 2.

- **In Vitro Dispersion Time**

The arranged tablet was finished by dropping the tablet in 10 ml estimating chamber containing 6 ml of reenacted salivary liquid (pH 6.8). Period necessary for complete scattering of tablet was estimated.

- **Dissolution Study**

In vitro appearance of Glipizide from tablets was seen by using 900 ml of reproduced intestinal fluid, SIF (USP phosphate support game plan, pH 7.4) at $37 \pm 0.5^\circ\text{C}$ and 50 rpm using programmable breaking down analyzer [Paddle type, model TDT-08L, Electro lab, (USP), India]. 5 ml Aliquots were pulled back at time breaks and were recharged quickly with a comparable volume of fresh support medium. Aliquots, following fitting debilitating, were analyzed spectrophotometric partner (UV-1700, Shimadzu, Japan) at 378 nm.

IV. RESULTS AND DISCUSSION

Five plans of glipizide were set up with various groupings of the four individual Sodium starch glycolate, Croscarmellose, Superdisintegrants. For each enumerating, the blend of drug and excipients were masterminded and surveyed for various parameters as explained before. The powder blend was stuffed using a prompt weight strategy. Mass thickness was found in the extent of $0.45 - 0.43 \text{ g/cm}^3$ and the tapped thickness between $0.35 - 0.38 \text{ g/cm}^3$.

Table 2: Characterization of Glipizide Tablets

Parameters	F1	F2	F3	F4	F5
Hardness (kg/cm ²)	3.01±0.24	3.24±0.56	2.91±0.22	3.11±0.54	3.67±0.12
Friability (%)	0.744±0.024	0.647±0.062	0.645±0.053	0.621±0.042	0.589±0.054
Weight variation (mg)	100±3	99±2	101±3	101±1	105±1
Thickness (mm)	3.51±0.013	3.44±0.075	3.67±0.045	3.45±0.046	3.53±0.041
Wetting time (s)	16.25±2.5	15.3±1.5	13.6±2.2	14.1±2.0	14.4±1.5
In-vitro dispersion time (s)	30.32±2.51	28.14±1.14	26.24±2.24	25.74±3.27	24.84±2.25

Hausner's proportion and compressibility index were determined. The compressibility index was found somewhere in the range of 13.27 and 20.32 and the compressibility index information demonstrated a genuinely decent flow ability of the powder mix. The great flow ability of the powder

mix was additionally proved with the edge of repose (slope of 20.12 – 25.97), which is underneath 40° showing great flow ability. Micromeritics aftereffects of all batches have appeared in Table 2.




Figure 1: Dissolution studies of prepared glipizide tablets (n=3)

Results are conveyed as mean±SD

The disintegration of arranged tablets was generally quick. These outcomes showed that disintegration parameter estimations of “sodium starch glycolate” and “croscarmellose sodium” comprising tablets are conflicting with the crumbling time estimates watched.

V. CONCLUSION

Building operators improve the textural attributes that thusly upgrade the breaking down in the mouth, other than; including mass likewise diminishes the grouping of the dynamic in the organization.

AUTHORS PROFILE



Dillip Kumar Brahma, Research Scholar, Dept. of Pharmacy, Sri Satya Sai University of Technology & Medical Sciences, Sehore, Bhopal-Indore Road, Madhya Pradesh, India.

Dr. Neeraj Sharma, Research Guide, Dept. of Pharmacy, Sri Satya Sai University of Technology & Medical Sciences, Sehore, Bhopal Indore Road, Madhya Pradesh, India.

The design specialists prescribed for this transport device should contain more sugar, eg. polydextrose, Mannitol, DCL (directly compressible lactose), lactitol and starch hydrolyzate to increase solubility, Fluid and tactile detection. The building operators account for between 10 and 90% by weight of the last structure. Emulsifying specialists are significant excipients for defining quick liquefying tablets they help in fast deterioration and medication discharge without biting, gulping or drinking water. Also, consolidating emulsifying specialists is helpful in balancing out the immiscible mixes and improving bio-availability. A comprehensive scope of emulsifiers is prescribed for the quick tablet definition, including sucrose esters, propylene glycol esters, alkyl sulfates, lecithin, and others. These operators can be consolidated in the scope of 0.05% to around 15% by weight of the last creation. Greases, however not basic excipients can additionally help with causing these tablets progressively attractive after they to break down in the mouth. Oils expel abrasiveness and aid the medication transport system starting from the mouth into the stomach. Flavors and taste-concealing operators make the items increasingly agreeable and satisfying for patients. The expansion of these fixings helps with beating sharpness and bothersome tastes of some dynamic fixings.

REFERENCES

1. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Supplement 1):S62–9.
2. Balaji V, Seshiah V, Sanjeevi CB, Balaji MS, Green A. Gestational diabetes mellitus in India. Japi 2004;52:707–11.
3. Barker DJP, Hales CN. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992;35(7):595–601.
4. Cornwall J, Kaveeshwar SA. The current state of diabetes mellitus in India. Australas Med J 2014;7(1):45.
5. CTR and Group DC. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977–86.
6. Eriksson JG, Tuomilehto J, Valle TT, Lindström J, Ilanne-Parikka P, Hämäläinen H, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343–50.
7. Group NDD. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28(12):1039–57.
8. Kapur A, Snehalatha C, Ramachandran A, Vijay V, Mohan V, Das AK, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001;44(9):1094–101.
9. Lakey JRT, Korbitt GS, Shapiro AMJ, Ryan EA, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343(4):230–8.
10. Meguro S, Otsuka K, Nagao T, Hase T, Komikado M, Tokimitsu I, et al. A catechin-rich beverage improves obesity and blood glucose control in patients with type 2 diabetes. Obes (Silver Spring) 2009;17(2):310–7.
11. Mohan V, Ponnaiya M, Rema M. Prevalence of retinopathy in non insulin dependent diabetes mellitus at a diabetes centre in southern India. Diabetes Res Clin Pract 1996;34(1):29–36.
12. Zimmet PZ, Alberti KGMM. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15(7):539–53.